Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: EyePoint, Inc.

Market Cap 1.03B 897M 827M 775M 1.45B 98.98B 1.48B 9.86B 3.82B 47.71B 3.88B 3.8B 166B P/E Ratio 2026 *
-3.48x
P/E Ratio 2027 * -4.43x
Enterprise Value 739M 642M 591M 554M 1.04B 70.8B 1.06B 7.06B 2.73B 34.13B 2.78B 2.72B 119B EV / Sales 2026 *
433x
EV / Sales 2027 * 16.5x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+10.20%
1 week+1.98%
Current month-6.36%
1 month-9.65%
3 months-17.37%
6 months-21.07%
Current year-31.92%
1 week 9.65
Extreme 9.65
10.4
1 month 9.45
Extreme 9.45
12
Current year 9.45
Extreme 9.45
15.27
1 year 7.01
Extreme 7.008
15.32
3 years 3.52
Extreme 3.525
28.6
5 years 2.08
Extreme 2.08
28.6
10 years 0.38
Extreme 0.382
35.98
Manager TitleAgeSince
Chief Executive Officer 68 2023-07-09
Director of Finance/CFO 61 2019-11-13
Chief Tech/Sci/R&D Officer 43 2024-03-03
Director TitleAgeSince
Director/Board Member 68 2016-09-14
Director/Board Member 68 2023-07-09
Chairman 77 2018-09-09
Change 5-day change 1-year change 3-year change Capi.($)
+5.10%+1.98% - - 1.03B
+2.16%+3.17%+43.57%+160.71% 1,013B
-0.07%+4.45%+53.50%+49.05% 574B
-0.08%-0.08%+17.37%+63.20% 397B
-0.37%+4.97%+21.24%+15.95% 324B
+0.85%+2.79%+24.89%+15.93% 280B
+2.10%+7.06%+24.57%+34.79% 273B
+4.84%+2.45%+21.33%+62.89% 182B
-0.19%+3.96%-45.64%-48.23% 194B
+3.61%-2.56%+15.16%+61.66% 151B
Average +2.47%+2.65%+19.56%+46.22% 376.52B
Weighted average by Cap. +1.42%+3.99%+29.41%+72.79%

Financials

2026 *2027 *
Net sales 1.71M 1.48M 1.37M 1.28M 2.39M 163M 2.44M 16.29M 6.31M 78.79M 6.41M 6.27M 274M 47.71M 41.4M 38.16M 35.76M 66.81M 4.57B 68.2M 455M 176M 2.2B 179M 175M 7.66B
Net income -311M -270M -249M -233M -436M -29.79B -445M -2.97B -1.15B -14.36B -1.17B -1.14B -49.93B -266M -231M -213M -200M -373M -25.49B -381M -2.54B -983M -12.29B -999M -978M -42.72B
Net Debt -294M -255M -235M -221M -412M -28.18B -421M -2.81B -1.09B -13.59B -1.1B -1.08B -47.24B -248M -215M -199M -186M -348M -23.77B -355M -2.37B -917M -11.46B -932M -912M -39.84B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change
26-06-11 10.30 +5.10%
26-06-10 9.800 +0.51%
26-06-09 9.750 -1.52%
26-06-08 9.900 -1.98%
26-06-05 10.10 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
12.33USD
Average target price
37.00USD
Spread / Average Target
+200.08%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!